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Delayed APC/C activation extends 
the first mitosis of mouse embryos
Anna Ajduk1,2, Bernhard Strauss1, Jonathon Pines1,3 & Magdalena Zernicka-Goetz1,4
The correct temporal regulation of mitosis underpins genomic stability because it ensures the alignment 
of chromosomes on the mitotic spindle that is required for their proper segregation to the two daughter 
cells. Crucially, sister chromatid separation must be delayed until all the chromosomes have attached 
to the spindle; this is achieved by the Spindle Assembly Checkpoint (SAC) that inhibits the Anaphase 
Promoting Complex/Cyclosome (APC/C) ubiquitin ligase. In many species the first embryonic M-phase is 
significantly prolonged compared to the subsequent divisions, but the reason behind this has remained 
unclear. Here, we show that the first M-phase in the mouse embryo is significantly extended due to a 
delay in APC/C activation. Unlike in somatic cells, where the APC/C first targets cyclin A2 for degradation 
at nuclear envelope breakdown (NEBD), we find that in zygotes cyclin A2 remains stable for a significant 
period of time after NEBD. Our findings that the SAC prevents cyclin A2 degradation, whereas over-
expressed Plk1 stimulates it, support our conclusion that the delay in cyclin A2 degradation is caused by 
low APC/C activity. As a consequence of delayed APC/C activation cyclin B1 stability in the first mitosis is 
also prolonged, leading to the unusual length of the first M-phase.
The time between NEBD and the onset of anaphase is one of the most important periods for genomic stability as 
the cell must ensure that all the chromosomes are attached to the mitotic spindle before sister chromatids sepa-
rate. This is achieved by regulating the activity of the key ubiquitin-ligase in mitosis, APC/C. In a typical mitotic 
division, the APC/C is activated at NEBD and one of its first substrates is cyclin A21, 2. Cyclin A2 is required for 
cells to enter M-phase and it is targeted by the APC/C even though the SAC is active, monitoring unattached 
chromosomes3, 4, and generating the Mitotic Checkpoint Complex (MCC) that inhibits the APC/C. Cyclin A2 can 
be degraded when the SAC is active because it can compete with the MCC component, BubR1, to bind Cdc205. 
The cyclin A2-Cdc20 complex then binds to the APC/C through a Cks protein6, 7. This mode of recognition allows 
cyclin A2 to be preferentially ubiquitylated by the APC/C over securin and cyclin B1, when APC/C activity is 
limited8.
By contrast, the timing of cyclin B1 and securin degradation is controlled by the SAC, which prevents the 
APC/C from recognising cyclin B1 and securin by inactivating Cdc20. One molecule of Cdc20 is incorporated 
into a complex with the Mad2, BubR1 and Bub3 proteins to form the MCC that itself can inhibit a second mole-
cule of Cdc209–13. Once all the chromosomes have attached correctly to the microtubules of the spindle through 
their kinetochores, the SAC is inactivated and Cdc20 is released to activate the APC/C against cyclin B1 and 
securin14, 15, leading to the activation of separase and subsequently M-phase exit. The SAC ensures that sister 
chromatids will segregate to opposite spindle poles once the cohesion complexes are cleaved by separase.
The first mitotic division is highly unique as it is markedly longer than subsequent divisions in many species, 
including mouse16, 17, Xenopus18, 19, sea urchins and nematodes19. In mouse embryos the first mitosis lasts for 
90–120 min, whereas the second lasts only 60–80 min16, 17. The human first embryonic mitosis is also very long 
(approximately 2,5–3hrs20–24), and although there are no published data on the length of the second embry-
onic mitosis, some observations confirm that it tends to be markedly shorter (R. Milewski, J. Czerniecki, S. 
Wołczyński, unpublished data). By comparison, in somatic cells the length of M-phase varies between 30 and 
60 min, depending on the cell type and on the length of the SAC-regulated prometaphase, i.e. the period when the 
spindle and correct kinetochore-microtubule attachments are formed25–29.
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One of the mechanisms that might prolong the first embryonic M-phase involves Emi2, an inhibitor of 
Cdc2030–32. The accumulation of Emi2 in metaphase II oocytes inhibits APC/C and thus maintains high levels 
of cyclin B1 and securin prior to fertilization33, 34. Sperm penetration releases the oocyte from the Emi2-induced 
M-phase arrest by triggering phosphorylation of Emi2 by Ca2+/calmodulin dependent kinase II (CaMKII) and 
Plk1, which subsequently targets it for degradation30, 35–37. Emi2 protein reappears in zygotes and it has been 
hypothesised that this contributes to the prolonged zygotic M-phase32, 38. Alternatively, zygotic M-phase has also 
been proposed to be prolonged by a pool of stable cyclin A2 that inhibits efficient ubiquitination of cyclin B1 and 
securin by the APC/C39, 40.
Here, we have investigated how the APC/C is regulated at the 1- to 2-cell transition in mouse embryos by 
assaying the degradation of cyclin A2 and cyclin B1. We find that, unlike in somatic cells, the APC/C does not 
appear to be activated at NEBD because we find cyclin A2 is stable in cells for over 30 min after NEBD, and cyc-
lin B1 is stable for more than 45 min. We show that this delay in APC/C activation is most likely not caused by 
residual Emi2 but instead depends on Plk1 activity. Moreover, our experiments reveal that cyclin A2 degradation 
is repressed by the SAC. Thus, we find that the prolonged first mammalian mitosis correlates with an unusual 
behaviour of the APC/C.
Results
Spatiotemporal dynamics of cyclin A2 and cyclin B1 in mouse zygotes. To determine how the 
very first embryonic M-phase is regulated, we assayed the spatiotemporal dynamics of cyclins A2 and B1. To this 
end, we injected zygotes or 2-cell embryos with synthetic mRNAs encoding either cyclin A2 tagged with YFP 
(cyclin A2-YFP), or cyclin B1 tagged with YFP or with Ruby (cyclin B1-YFP and cyclin B1-Ruby) and filmed their 
development through the first two mitotic divisions. We found that cyclin A2 was localized in zygotic pronuclei 
during interphase, released into the cytoplasm during NEBD, degraded before the onset of anaphase, then resyn-
thesized and imported into nuclei after the completion of division (Fig. 1a, Supplementary Video S1). In 2-cell 
embryos cyclin A2 degradation started at NEBD, exactly as in somatic cells1, 2, but in zygotes it was significantly 
delayed (median of 39.0 min post NEBD, p < 0.001) and subsequently proceeded at a slow rate (Fig. 1a,c, Table 1). 
The observation that cyclin A2 remained stably expressed at a high level for over 30 min after NEBD in zygotes 
indicated that activation of APC/C was delayed rather than partially activated. In the latter situation, cyclin A2 
degradation would be initiated at the NEBD but proceed with slower kinetics.
Assaying cyclin B1 showed that it was excluded from the nucleus for most of interphase and imported into 
the nucleus during prophase, approximately 30 min before NEBD. At NEBD cyclin B1 was released into the cyto-
plasm and bound the mitotic apparatus (Fig. 1b, Supplementary Video S2). We found that cyclin B1 was degraded 
at a similar rate during the first and second mitotic divisions (Fig. 1d), but, as with cyclin A2, the onset of cyclin 
B1 degradation in the first mitotic division was significantly delayed in comparison to the second mitotic division 
(medians of 48.0 and 18.0 min from NEBD, respectively, p < 0.001, Fig. 1b,d, Table 2). The delay in the degrada-
tion of cyclin A2 and cyclin B1 corresponded to the prolonged duration of the whole M-phase in zygotes when 
compared to 2-cell embryos (medians of 111.0 and 57.0 min, respectively, p < 0.001, for cyclin A2-YFP embryos, 
and 96.0 and 76.5 min, p < 0.001, for cyclin B1-Ruby embryos, Tables 1 and 2). However, when we tested the 
correlation between the onset time of cyclin degradation and the duration of M-phase, we found that only the 
delay in cyclin B1 degradation, and not in cyclin A2 degradation, correlated with the length of M-phase (R = 0.67, 
p < 0.001). Taken together these results indicate that the prolonged duration of the first mitotic division might be 
caused by the delayed degradation of cyclin B1.
Delayed degradation of cyclin A2 does not affect the timing of cyclin B1 degradation. As late 
degradation of cyclin A2 did not seem to correlate with prolongation of the first embryonic M-phase, we directly 
addressed whether the high levels of cyclin A2 in zygotes after NEBD might reduce the ability of the APC/C to 
ubiquitylate cyclin B1 and delay its degradation. To test this hypothesis, we examined the effect of over-expressing 
cyclin A2 on the rate of cyclin B1 degradation. To this end, zygotes were injected with mRNA encoding cyclin 
B1-Ruby and various concentrations (0.0–0.4 μg/μl) of mRNA encoding cyclin A2-YFP. The increasing concen-
trations of mRNA translated into increasing amounts of cyclin A2 protein as judged by an increase in fluorescence 
signal (Fig. 2a). We found that over-expressing cyclin A2-YFP did not change the onset of cyclin B1-Ruby degra-
dation (Fig. 2a, Table 2). We next followed degradation of cyclin B1-Ruby and cyclin A2-YFP simultaneously in 
zygotes. This revealed that cyclin B1-Ruby started to be degraded on average 3 min after cyclin A2 degradation, 
and at that time the level of cyclin A2 had only decreased on average by 0.7% (Fig. 2b). These results indicated that 
the delay in cyclin B1 degradation was not due to the late degradation of cyclin A2.
The SAC controls both cyclin B1 and cyclin A2 degradation. In somatic cells a strong SAC signal 
does not prevent cyclin A2 degradation, although it slows it down41, but it does prevent cyclin B1 degradation8, 14. 
Since degradation of both cyclin A2 and B1 was delayed in the first embryonic M-phase, we wished to investigate 
whether the SAC was responsible for this. To test this hypothesis, we determined the effect of inhibiting the Mps1 
kinase, an essential activator of the SAC42, 43, on the dynamics of cyclin A2 and cyclin B1 degradation. We injected 
zygotes with cyclin A2-YFP or cyclin B1-Ruby and assayed their development in the presence of reversine, an 
Mps1 inhibitor42. We found that inhibiting the SAC shortened the period between NEBD and the onset of cyclin 
B1-Ruby degradation (to the median of 39 min, p < 0.05, Fig. 3a, Table 2). Similarly, reversine accelerated the 
onset of securin-GFP degradation (from the median of 36 min to 24 min, p < 0.001; Supplementary Fig. S1a, 
Supplementary Table S1). Unlike in somatic cells, ablating the SAC in zygotes advanced the timing of cyclin 
A2-YFP degradation (to the median of 3 min, p < 0.001, Fig. 3b). We concluded that the SAC affects the tim-
ing of the cyclin B1 and A2 degradation and thus might be partially responsible for the prolonged first mouse 
embryonic M-phase. Inactivation of the SAC during the first division did not, however, shorten the time between 
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NEBD and the onset of cyclin B1 or cyclin A2 degradation to the length comparable with the period observed 
in the subsequent division (p < 0.001 and p < 0.05 respectively, Tables 1 and 2). This indicated that there was an 
additional mechanism regulating the onset of cyclin B1 and A2 degradation and, in consequence, the length of 
the first M-phase.
Figure 1. Spatiotemporal dynamics of cyclins A2 and B1 in mouse embryos (a) Spatiotemporal dynamics 
of cyclin A2-YFP in dividing zygotes. Selected images from a time-lapse recording, time shown in hours and 
minutes counted from the timepoint of nuclear envelope breakdown (NEBD). (b) Spatiotemporal dynamics 
of cyclin B1-YFP in dividing zygotes. Selected images from a time-lapse recording, time shown in hours and 
minutes counted from the timepoint of NEBD. (c) Quantification of cyclin A2-YFP degradation in 1- and 2-cell 
embryos, averaged from 30 and 37 embryos respectively. (d) Quantification of cyclin B1-Ruby degradation in 
1- and 2-cell embryos, averaged from 55 and 31 embryos respectively. Scale bars in (a) and (b) are 20 µm. Plots 
in (c) and (d) show mean values + /− standard deviation.
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Emi2 is not involved in regulation of the first embryonic M-phase. The first mechanism we con-
sidered was APC/C inhibition by maternal Emi2, which is responsible for maintaining oocytes in metaphase II. 
It had previously been suggested that prolongation of the first embryonic M-phase was caused by the persistence 
of Emi2 that is resynthesized in zygotes after its degradation triggered by fertilisation32. To address whether Emi2 
was responsible for the delay in cyclin degradation and the prolonged zygotic M-phase, we depleted Emi2 with 
specific morpholinos (Emi2 MO), which had been shown to block the translation of Emi2 mRNA33. Since Emi2 
is required to inhibit the APC/C and maintain oocytes in metaphase II, we assayed the effectiveness of the Emi2 
MO to deplete Emi2 by co-injecting Emi2 MO with cyclin B1-YFP into metaphase II oocytes and measured the 
level of cyclin B1-YFP fluorescence and oocyte activation. We found that 75% of oocytes injected with Emi2 MO 
(33/44), but only 9% (2/22) oocytes injected with a control MO (Emi2 MO with 5 mismatched pairs of nucleo-
tides, Emi2 5-MP MO) underwent activation within 24 hrs of injection (Supplementary Fig. S2a). Moreover, there 
was an abrupt decrease in cyclin B1-YFP 12 hrs after microinjection of Emi2 MO, whereas in oocytes co-injected 
with Emi2 5-MP MO cyclin B1 remained stable (Supplementary Fig. S2b). These results demonstrated that we 
could efficiently deplete Emi2 through this approach. We injected Emi2 MO into very early zygotes, 2 h post 
fertilization and well before pronuclei formation, at the time, when Emi2 protein is completely degraded33. This 
ensured that the morpholinos were injected in time to prevent re-synthesis of Emi2 after its degradation at mei-
otic exit32, 33. We found that zygotes injected with Emi2 MO behaved exactly as the control-injected zygotes with 
no shortening of the M-phase and no difference in the timing of cyclin B1 degradation (medians of 40 and 45 min, 
respectively, p > 0.05, Fig. 4a).
As a further test of the potential role of Emi2 in prolonging M-phase, we depleted Emi2 by siRNA. To this 
end, we injected GV stage oocytes with mRNA encoding securin-GFP together with siRNA specific for Emi2 
or control siRNA, allowed them to mature in vitro until metaphase II, then activated them parthenogenetically 
and assayed them through the first embryonic division. Emi2 depletion did not accelerate the onset of securin 
degradation (Supplementary Fig. S3a,b), even though the efficiency of Emi2 siRNA was confirmed by its ability to 
release metaphase II arrest in injected oocytes (Supplementary Fig. S3c). Taken together, these results show that 
Emi2 is unlikely to be responsible for the delay in degradation of APC/C substrates during the first embryonic 
M-phase.
Plk1 controls both cyclin B1 and cyclin A2 degradation in a SAC-independent manner. We then 
tested the possibility that Plk1 might be responsible for the delay in cyclin degradation because it is important 
Experimental 
conditions Total no.
Time between NEBD and 
cyclin A2 degradation 
(min; median (Q1; Q3))
Time between NEBD and 
anaphase (min; median (Q1; Q3))
1-cell
control 30 39.0 (30.0; 54.0) 111.0 (99.8; 117.0)
reversine 31 3.0 (0.0; 19.5)b 99.0 (93.0; 108.0)
wt Plk1 OE 22 15.0 (0.0; 26.3)a 108.0 (105.0; 117.0)
BI2536 38 — —
2-cell control 37 0.0 (0.0; 0.0)b,c,e 57.0 (51.0; 63.0)b,d,f
Table 1. Mitotic timings in mouse embryos injected with cyclin A2-YFP. ap < 0.05 comparing to control 1-cell 
embryos, bp < 0.001 comparing to control 1-cell embryos, cp < 0.05 comparing to reversine-treated 1-cell 
embryos, dp < 0.001 comparing to reversine-treated 1-cell embryos, ep < 0.05 comparing to 1-cell embryos over-
expressing wt Plk1, fp < 0.001 comparing to 1-cell embryos over-expressing wt Plk1.
Experimental conditions
Total 
no.
Time between NEBD and cyclin B1 
degradation (min; median (Q1; Q3))
Time between NEBD and 
anaphase (min; median (Q1; Q3))
1-cell
control 55 48.0 (40.5; 52.5) 96.0 (87.0; 105.0)
reversine 57 39.0 (30.0; 45.0)b 87.0 (81.0; 96.0)
wt Plk1 OE 38 28.5 (24.0; 33.0)a 78.0 (75.0; 92.3)a
kd Plk1 OE 11 45.0 (39.0; 51.0) 87.0 (82.5; 99.0)
BI2536 12 93.0 (83.3; 100.5)b —
BI2536 + reversine 15 90.0 (87.0; 103.5)b —
cyclin A2 OE 
(0.07 µg/µl) 41 48.0 (45.0; 51.0) 115.5 (105.8; 128.3)
a
cyclin A2 OE 
(0.2 µg/µl) 12 54.0 (44.3; 60.8) 117.0 (111.0; 135.0)
e
cyclin A2 OE 
(0.4 µg/µl) 10 54.0 (51.8; 67.5) —
2-cell control 31 18.0 (15.0; 24.0)a,c 76.5 (69.8; 81.0)a,d
Table 2. Mitotic timings in mouse embryos injected with cyclin B1-Ruby. ap < 0.001 comparing to control 
1-cell embryos, bp < 0.05 comparing to control 1-cell embryos, cp < 0.001 comparing to reversine-treated 1-cell 
embryos, dp < 0.05 comparing to reversine-treated 1-cell embryos, evalues calculated only for embryos that 
completed cytokinesis (9 out of 12).
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for the full activation of the APC/C44-46. Moreover, Plk1 is essential for the completion of the first embryonic 
cell cycle in the mouse47, 48. To examine whether Plk1 might be involved in regulating cyclin B1 and A2 turn-
over in the first M-phase in mouse, we injected zygotes with mRNAs encoding wt Plk1 and cyclins (A2 or B1) 
and then assayed their development. We found that over-expression of wt Plk1-YFP shortened the period 
between NEBD and the onset of cyclin B1-Ruby degradation to the length typical for the second M-phase (to a 
median of 28.5 min, p < 0.001 when compared to the first M-phase and p > 0.05 when compared to the second 
M-phase; Fig. 4b, Table 2). The duration of the whole M-phase was also shortened accordingly (to a median of 
78.0 min, p < 0.001 when compared to the first M-phase and p > 0.05 when compared to the second M-phase, 
Table 2). Over-expression of an inactive, kinase dead Plk1 (kd Plk1-YFP) did not affect the degradation of cyclin 
B1 (Fig. 4b, Table 2), indicating that the observed acceleration of cyclin B1 degradation required Plk1 activity. 
Over-expression of wt Plk1-TagRFP also advanced the onset of securin degradation (to a median of 27.0 min, 
p < 0,05; Supplementary Fig. S1b, Supplementary Table S1). Remarkably, we found that although Plk1 is not 
required for cyclin A2 to be degraded in somatic cells49, over-expressing Plk1-TagRFP significantly accelerated 
the onset of cyclin A2-YFP degradation in zygotes (to a median of 15 min post NEBD, p < 0.05) (Fig. 4c, Table 1), 
although it still occurred on average later than in 2-cell embryos (p < 0.05, Table 1).
As a further test of whether Plk1 was involved in regulating the first embryonic M-phase, we inhibited Plk1 
with the small molecule inhibitor BI253649 and assessed zygotic division by time-lapse microscopy. This revealed 
that BI2536 significantly delayed the onset of cyclin B1 degradation (to a median of 93.0 min post NEBD, p < 0.05; 
Fig. 4b, Table 2). Although we observed some gradual decrease of cyclin B1 in zygotes treated with BI2536, it was 
Figure 2. Role of cyclin A2 in regulation of cyclin B1 degradation (a) Quantification of cyclin B1-Ruby 
degradation in zygotes injected with increasing concentrations (0, 0.07 μg/μl, 0.2 μg/μl, 0.4 μg/μl) of cyclin 
A2-YFP mRNA, averaged from 55, 41, 12 and 10 embryos respectively. Plots show mean values +/− standard 
deviation. Images show representative zygotes injected with increasing concentrations of cyclin A2-YFP 
mRNA and the same concentration of cyclin B1 mRNA. Over-expression of cyclin A2 was confirmed by an 
immunostaining (the bottom panel). Scale bar is 100 μm. (b) Quantification of cyclin B1-Ruby and cyclin A2-
YFP degradation in a single representative zygote.
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never sufficient to induce anaphase (Supplementary Fig. S4a). The inhibition of Plk1 also prevented the degrada-
tion of cyclin A2, which persisted at a high level for over 2 h post NEBD (Fig. 4c, Table 1). We found that inhib-
iting Plk1 activity did not interfere with the formation of a bi-polar spindle, in agreement with a recent report48. 
However, we found that the spindle gradually deteriorated during the prolonged M-phase arrest; specifically the 
spindle poles became less focused over time and displayed increased numbers of astral microtubules, and in some 
cases chromosomes were displaced from the metaphase plate (Supplementary Fig. S4a).
To address whether Plk1 altered the length of the first M-phase by altering SAC activity, we asked whether 
reversine could override the zygotic M-phase arrest induced by Plk1 inhibition. We found that neither reversine, 
nor injection of mRNA encoding a dominant negative Mad2 (dn Mad2), was able to release zygotes from a 
BI2536-induced M-phase arrest (Supplementary Fig. S4b). Moreover, reversine was not able to counteract the 
BI2536-induced delay in cyclin B1 degradation (Fig. 4d, Table 2).
Finally, since our results indicated that Plk1 activity might be limiting in the first M-phase of the mouse 
embryo, we investigated whether the amount of active Plk1 (i.e. Plk1 phosphorylated at Thr210) differs between 
M-phase zygotes and 2-cell embryos. Quantitative analysis of the intensity of phospho-Plk1 (pPlk1) immunos-
taining indicated that active Plk1 was slightly more abundant in M-phase 2-cell embryos than in M-phase zygotes, 
although the difference did not reach statistical significance (p = 0.058; Supplementary Fig. S5a,b). Interestingly, 
we observed that there was a subtle, but potentially important, difference in pPlk1 localization in 1- and 2-cell 
stage embryos. In both the first and the second M-phase pPlk1 localized to the spindle poles and chromosomes; 
however, in 2-cell embryos it strongly accumulated on kinetochores, whereas in zygotes its chromosomal distri-
bution was more diffuse (Supplementary Figure S5c).
Taken together these results indicate that the degradation of cyclins B1 and A2, and in consequence the pro-
longed first M-phase, is regulated by a Plk1-dependent mechanism. We propose that a difference in the localiza-
tion of active Plk1 might potentially be involved in prolongation of the first embryonic M-phase in the mouse.
Discussion
The first embryonic mitosis in a number of species is strikingly longer than the subsequent embryonic mitoses 
and mitosis in somatic cells19, 50. Indeed, the first zygotic M-phase is unique because during this period two sets 
of chromosomes, enclosed in separate nuclei, need to form a single metaphase plate. This process is more compli-
cated than its equivalent in a typical mononuclear somatic cell, and therefore most likely more time is required to 
ensure appropriate chromosome-spindle connections. It appears plausible to us that this is the biological purpose 
of the prolonged first zygotic M-phase, and particularly the period between NEBD and cyclin B1 degradation.
Here, we have uncovered atypical APC/C behaviour in the first mitotic division that appears to be responsible 
for this extended M-phase. Our analysis of the spatiotemporal dynamics of cyclin A2 and cyclin B1 indicates 
that length of the first M-phase is likely a consequence of delayed APC/C activation. We find that cyclin A2 
starts to be degraded in zygotes over 30 min after NEBD, in striking contrast to 2-cell embryos or somatic cells 
where cyclin A2 begins to be degraded at NEBD. The degradation of cyclin B1 and securin in zygotes is also 
significantly delayed in comparison to mitosis in 2-cell embryos, and to somatic cells8, 14. Although it has been 
hypothesized that the stable pool of cyclin A2 is responsible for the prolonged M-phase in zygotes39, 40, our results 
do not support this idea because we find that cyclin B1 starts to be degraded when the levels of cyclin A2 are still 
very high. Furthermore, over-expressing cyclin A2 does not delay the onset of cyclin B1 degradation. However, 
Figure 3. Role of SAC in regulation of cyclin A2 and B1 degradation (a) Quantification of cyclin B1-Ruby 
degradation in control zygotes and zygotes treated with reversine averaged from 55 and 57 embryos respectively. 
(b) Quantification of cyclin A2-YFP degradation in control zygotes and zygotes treated with reversine averaged 
from 30 and 31 embryos respectively. Plots in (a) and (b) show mean values +/− standard deviation.
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in accordance with published data1, 2, 51 we observed that over-expression of cyclin A2 disturbs progression of 
anaphase and cytokinesis.
Our experiments provide evidence that the SAC regulates APC/C activity towards cyclin A2 in the first 
M-phase in mouse because inhibiting the SAC both advances and accelerates the degradation of cyclin A2 (and 
B1). However, our results also indicate that SAC activity is not solely responsible for the prolongation of the 
zygotic M-phase since inhibiting the SAC accelerated the onset of cyclin degradation by only approximately 
10–20 min. This agrees with earlier work showing that SAC proteins, such as Mad2 leave, the kinetochores in 
zygotes within approximately 20 min of NEBD17, and a similar delay in cyclin B1 degradation is caused by the 
SAC in somatic cells27, 29. Thus, there must be another mechanism involved in the delay in degradation of cyclins 
A2 and B1, and as a result, the prolongation of zygotic M-phase.
Figure 4. Role of Emi 2 and Plk1 in the regulation of cyclin A2 and B1 degradation (a) Time between NEBD and 
the onset of cyclin B1-YFP degradation in zygotes injected with Emi2 MO and Emi2–5MP MO, averaged from 
28 and 11 embryos respectively. The boxes show medians and the first and third quartiles. The whiskers are set at 
1.5*IQR above the third and below the first quartile. Outlier values are marked with dots. (b) Quantification  
of cyclin B1-Ruby degradation in control zygotes, zygotes injected with wt Plk1-YFP or kd Plk1-YFP, and 
zygotes treated with BI2536, a Plk1 inhibitor, averaged from 55, 38, 11 and 12 embryos respectively. (c) 
Quantification of cyclin A2-YFP degradation in control zygotes, zygotes injected with wt Plk1-TagRFP and 
zygotes treated with BI2536, averaged from 30, 22 and 38 embryos respectively. (d) Quantification of cyclin B1-
Ruby degradation in control zygotes and zygotes treated with BI2536 or BI2536 and reversine, averaged from 
55, 12, and 15 embryos respectively. Plots in (b–d) show mean values +/− standard deviation.
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Our evidence implicates Plk1 as the additional factor responsible for the first mitotic delay. Plk1 activity 
appears to be a limiting factor because over-expression of Plk1 accelerates the onset of cyclin A2 and B1 degra-
dation, even though in somatic cells Plk1 activity is not required for the APC/C to target cyclin A2 at NEBD49, 52. 
Moreover, Plk1 over-expression shortens the period between NEBD and the onset of cyclin B1-Ruby degrada-
tion to the length typical for the second embryonic mitosis. We show that Plk1 does not act exclusively through 
the SAC, since ablation of the SAC does not rescue the delay caused by Plk1 inhibition. Plk1 is also unlikely to 
act through Emi2 since the injection of Emi2-specific morpholinos or siRNAs did not accelerate cyclin B1 or 
securin degradation during the first embryonic division. However, we cannot completely exclude the possibility 
that in zygotic M-phase even a very small amount of Emi2 that potentially may remain in the cell after MO- or 
siRNA-induced depletion is sufficient to inhibit APC/C activity. Indeed, the role of Emi2 in the first mitotic divi-
sions is currently debated in Xenopus embryos34, 53. Instead, our evidence would be congruent with a role for Plk1 
in activating the APC/C in embryonic divisions through direct phosphorylation of the APC/C complex45, 46, 52, 54.
If Plk1 is indeed a limiting factor in the zygotic M-phase, then it should either be expressed at lower levels in 
zygotes, or be differently regulated. Analysis of transcriptomic data available in the DBTMEE database (RNA-seq 
Ver2_FPKM collection, http://dbtmee.hgc.jp/)55 indicates that Plk1 mRNA expression is higher in zygotes than in 
2-cell embryos, but we find that the amount of active Plk1 is comparable – with a tendency to be lower - between 
M-phase zygotes and 2-cell embryos. Comparing the expression of Plk1 activators / inhibitors also does not 
reveal a clear difference between these two stages: some transcripts are more abundant in zygotes, others in 2-cell 
embryos. Alternatively, the difference between the mode of Plk1 action in the first and the second embryonic 
divisions may relate to the distribution of active Plk1: in contrast to 2-cell embryos, in zygotes, pPlk1 does not 
accumulate very effectively on kinetochores.
Taken together, we conclude that the APC/C has reduced activity in the first embryonic division that extends 
the first M-phase. As a consequence we find that cyclin A2 degradation in the first mitosis is atypical, resembling 
the way in which cyclin B1 is controlled in somatic cells, because its degradation is regulated by both SAC and 
Plk1 activities. Our observations shed new light on the molecular machinery controlling the unusual length of 
the first embryonic division.
Methods
Embryo collection and culture. All experimental procedures applied to animals were approved by the 
Home Office (UK) or by the Local Ethical Committe no. 1 (Warsaw, Poland), and were performed in compliance 
with the national regulations. Mouse F1 (C57Bl6 x CBA) females were superovulated by an intraperitoneal injec-
tion of 10 IU of pregnant mare serum gonadotrophin (PMSG, Intervet) followed 48 hrs later by 10 IU of human 
chorionic gonadotrophin (hCG, Intervet) and mating with F1 males. Zygotes and 2-cell embryos were recovered 
from oviducts into M2 medium 16–20 hrs and 44 hrs after hCG injection, respectively. MII oocytes were recov-
ered 15 hrs post hCG injection from oviducts of unmated females into M2 medium. GV oocytes were recovered 
from ovaries 48 hrs after the PMSG injection into M2 medium supplemented with 150 μg/ml dibutyryl cyclic 
AMP (dbcAMP, Sigma-Aldrich).
Microinjections and live imaging of embryos. Constructs encoding cyclin B1 tagged with YFP or Ruby 
(cyclin B1-YFP, cyclin B1-Ruby), cyclin A2 tagged with YFP (cyclin A2-YFP), Plk1 tagged with YFP or TagRFP 
(wt Plk1-YFP, wt Plk1-TagRFP), kinase dead version of Plk1 tagged with YFP (kd Plk1-YFP), dominant negative 
version of Mad2 (dn Mad2) and securin tagged with GFP (securin-GFP) were cloned into pBluescript RN3P vec-
tor and mRNA was synthesized from the T3 promotor using mMessage mMachine T3 kit (Ambion), as described 
previously56. A construct encoding histone 2B tagged with RFP (H2B-RFP) was cloned into pGEMHE vector and 
synthesized from the T7 promotor using mMessage mMachine T7 kit (Ambion). mRNAs (needle concentration 
0.025 μg/μl for H2B-RFP, 0.07 μg/μl for cyclin B1-Ruby, 0.07 μg/μl for cyclin A2-YFP, 0.2 μg/μl for cyclin B1-YFP, 
wt Plk1-YFP and kd Plk1-YFP, 0.35 μg/μl for securin-GFP, 0.7 μg/μl for Plk1-TagRFP, 0.8 μg/μl dn Mad2) were 
injected into a zygote or one blastomere of a 2-cell stage embryo and injected embryos were subsequently cultured 
in KSOM (Speciality Media, Millipore) for approximately 6 hrs to allow for sufficient protein expression. In some 
experiments oocytes or embryos were injected with 25 μM siRNA (Sigma-Aldrich) or 2 mM morpholino33 (Gene 
Tools LLC) specific to Emi2 and with appropriate controls (Supplementary Table S2). Emi2 MO was injected into 
early zygotes (recovered 16 hrs post hCG) together with cyclin B1-YFP, which then were cultured for approxi-
mately 8 hrs in KSOM. Emi2 siRNA was injected with securin-GFP into GV oocytes that were afterwards allowed 
to mature for 16 hrs and subsequently were activated parthenogenetically by incubation in 8% ethanol for 8 min 
and cultured for 8 hrs in KSOM. Zygotes, parthenogenotes or 2-cell embryos were transferred into M2 medium 
and imaged in 11–13 planes (5–6 µm apart) every 3–15 min for 12 hrs over the transition from 1- to 2-cell stage or 
2- to 4-cell stage. In some experiments M2 was supplemented with 500 nM reversine (Sigma-Aldrich) or 100 nM 
BI2536 (Axon Medchem). Imaging was performed on a 3i Intelligent Imaging Solutions spinning-disc confocal 
microscope, Zeiss Axiovert fluorescence microscope or Deltavision fluorescence microscope, all equipped with 
environmental chambers maintaining temperature of 37.5 °C.
Immunostaining. Embryos were fixed in 4% PFA (30 min, RT), permeabilised with 0.5% Triton-X100 
(30 min, RT) and blocked with 3% BSA. Plk1 phosphorylated at Thr210 was labeled with a polyclonal rabbit anti-
body (ThermoFisher Scientific; dilution 1:100 in 3% BSA, overnight, 4 °C) and cyclinA2 - with a polyclonal rabbit 
antibody (Santa Cruz; dilution 1:50 in 3% BSA, overnight, 4 °C), both followed by a secondary anti-rabbit anti-
body conjugated with Alexa 633 (Molecular Probes, ThermoFisher Scientific; dilution 1:200 in 3% BSA, 1.5 h, RT). 
Microtubules were stained with mouse anti-tubulin β antibody labeled with FITC (Sigma-Aldrich; dilution 1:50 in 
3% BSA, 1.5 h, RT or overnight, 4 °C). DNA was stained with Hoechst 33342 dye (Molecular Probes, ThermoFisher 
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 9682  | DOI:10.1038/s41598-017-09526-1
Scientific; 100ng/µl in PBS, 30 min, RT or overnight, 4°C), propidium iodide (Sigma-Aldrich; 3 μg/ml 
in PBS, 30 min, RT) or chromomycin A3 (Sigma-Aldrich; 10 μg/ml, 30 min, RT or overnight, 4°C). In case of 
phospho-Plk1 detection, a PhosStop solution (Roche) was added to all stages of immunostaining to inhibit 
phosphatases.
Statistical analysis. In order to quantify cyclin B1 or cyclin A2 levels in embryos, projections (sums of all 
slices) were prepared for all imaged embryos and mean fluorescence intensity was measured for each projection 
over the time of recording. The intensity values were then standardized with the fluorescence intensity at the 
NEBD. Polynomial curves were fitted to the data and the onset of cyclin or securin degradation was established 
as the first time-point after NEBD when the fluorescence decrease between two subsequent measurements was 
at least 0.01. Statistical analyses of results were performed using Student’s t-test, chi-squared test, Spearman’s 
rank-order correlation and Kruskal-Wallis test with a post-hoc multiple comparison of mean ranks test.
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